Characterizing the immune microenvironment of malignant peripheral nerve sheath tumor by PD-L1 expression and presence of CD8+ tumor infiltrating lymphocytes. [PDF]
, 2016 BackgroundMalignant peripheral nerve sheath tumor (MPNST) is an aggressive sarcoma with few treatment options. Tumor immune state has not been characterized in MPNST, and is important in determining response to immune checkpoint blockade.
Bernthal, Nicholas +11 more
core +2 more sources
Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer [PDF]
Clinical Cancer Research, 2005 Abstract Purpose: The negative regulatory programmed death-1/programmed death-1 ligand (PD-1/PD-L) pathway in T-cell activation has been suggested to play an important role in tumor evasion from host immunity. In this study, we investigated the expression of PD-L1 and PD-L2 in human esophageal cancer to define their clinical significance
Yuichiro, Ohigashi +14 more
openaire +2 more sources
Frontiers in Immunology, 2017 Functional impairment of T-cells and a concomitant augmented expression of programmed death-1 (PD-1) have been observed in visceral leishmaniasis patients, as well as in experimental models for visceral and cutaneous leishmaniasis.
Christodoulos Filippis +7 more
doaj +1 more source
Diagnostics, 2021 Periampullary cancers (PACs) are characterized by tumor-infiltrating lymphocytes (TILs), severe fibrosis, and epithelial to mesenchymal transition (EMT).
Nishant Thakur +3 more
doaj +1 more source
PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation. [PDF]
, 2016 A new approach to the management of non-small-cell lung cancer (NSCLC) has recently emerged that works by manipulating the immune checkpoint controlled by programmed death receptor 1 (PD-1) and its ligand programmed death ligand 1 (PD-L1).
Booton, R +11 more
core +2 more sources
Tzu Chi Medical Journal, 2023 Objectives: This study aimed to investigate the efficacy and safety of programmed cell death-1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors in patients with advanced hepatocellular carcinoma (HCC).
Tzu-Rong Peng, Li-Jou Yang, Ta-Wei Wu
doaj +1 more source
Posttranslational Modifications in PD-L1 Turnover and Function: From Cradle to Grave
Biomedicines, 2021 Programmed death-ligand 1 (PD-L1) is one of the most classic immune checkpoint molecules. Cancer cells express PD-L1 to inhibit the activity of effector T cells’ cytotoxicity through programmed death 1 (PD-1) engagement in exposure to inflammatory ...
Xinfang Yu +3 more
doaj +1 more source
Autophagy is activated and involved in cell death with participation of cathepsins during stress-induced microspore embryogenesis in barley [PDF]
, 2018 Microspores are reprogrammed towards embryogenesis by stress. Many microspores die after this stress, limiting the efficiency of microspore embryogenesis. Autophagy is a degradation pathway that plays critical roles in stress response and cell death.
Berenguer, Eduardo +4 more
core +1 more source
D-1 / PD-L1 EXPRESSION IN INVASIVE BREAST CARCINOMA / CANCER
Pakistan Armed Forces Medical Journal, 2021 Objective: To investigate the immunohistochemical expression of PD-1 and PD-L1 in breast cancer cases and its correlation with clinicopathological factors. Study Design: Cross sectional study. Place and Duration of Study: Histopathology department,
Sammeen Salim +3 more
doaj +1 more source
M2I-1 disrupts the in vivo interaction between CDC20 and MAD2 and increases the sensitivities of cancer cell lines to anti-mitotic drugs via MCL-1s [PDF]
, 2019 Background Drugs such as taxanes, epothilones, and vinca alkaloids are widely used in the treatment of breast, ovarian, and lung cancers but come with major side effects such as neuropathy and loss of neutrophils and as single agents have a lack of ...
Dang, Nanmao +7 more
core +1 more source